Global Disparities in Hepatitis B Elimination—A Focus on Africa

In 2016, WHO member states at the World Health Assembly adopted a Global Health Sector Strategy that included a policy of eliminating viral hepatitis. Clear targets were established to assist in achieving this by 2030. The strategy, while achievable, has exposed existing global disparities in healthcare systems and their ability to implement such policies. Compounding this, the regions with most disparity are also those where the hepatitis B prevalence and disease burden are the greatest. Foundational to hepatitis B elimination is the identification of both those with chronic infection and crucially pregnant women, and primary prevention through vaccination. Vaccination, including the birth dose and full three-dose coverage, is key, but complete mother-to-child transmission prevention includes reducing the maternal hepatitis B viral load in the third trimester where appropriate. Innovations and simplified tools exist in order to achieve elimination, but what is desperately required is the will to implement these strategies through the support of appropriate investment and funding. Without this, disparities will continue.

[1]  G. Gartlehner,et al.  [Prevention of Mother-To-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy]. , 2022, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).

[2]  T. Hallett,et al.  The impact of the timely birth dose vaccine on the global elimination of hepatitis B , 2021, Nature Communications.

[3]  F. Simon,et al.  Analytical validation of hepatitis B core‐related antigen (HBcrAg) using dried blood spots (DBS) , 2021, Journal of viral hepatitis.

[4]  P. Easterbrook,et al.  Eliminating mother-to-child transmission of human immunodeficiency virus, syphilis and hepatitis B in sub-Saharan Africa , 2021, Bulletin of the World Health Organization.

[5]  M. Buti,et al.  Incremental value of HBcrAg to classify 1582 HBeAg‐negative individuals in chronic infection without liver disease or hepatitis , 2021, Alimentary pharmacology & therapeutics.

[6]  J. Lourenço,et al.  The global impact of the COVID-19 pandemic on the prevention, diagnosis and treatment of hepatitis B virus (HBV) infection , 2021, BMJ Global Health.

[7]  N. Schmit,et al.  The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups , 2020, International journal of epidemiology.

[8]  R. Malekzadeh,et al.  The case for simplifying and using absolute targets for viral hepatitis elimination goals , 2020, Journal of viral hepatitis.

[9]  R. Chou,et al.  Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. , 2020, The Lancet. Infectious diseases.

[10]  M. Hellard,et al.  Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study. , 2020, The Lancet. Global health.

[11]  M. Buti,et al.  Assay for Hepatitis B Core-related Antigen Identify Patients With High Viral Load: Systematic Review and Meta-analysis of Individual Participant Data. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  S. Taylor-Robinson,et al.  Hepatitis B in sub‐Saharan Africa—How many patients need therapy? , 2019, Journal of viral hepatitis.

[13]  L. Ferradini,et al.  Integrated approach for triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis is highly effective and cost-effective: an economic evaluation. , 2019, International journal of epidemiology.

[14]  M. Lemoine,et al.  An appraisal of the WHO hepatitis B treatment guidelines applicability to Africans. , 2019, Journal of hepatology.

[15]  S. Nsanzimana,et al.  Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa. , 2019, Journal of hepatology.

[16]  N. Berhe,et al.  The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia. , 2019, Journal of hepatology.

[17]  Maimuna Mendy,et al.  Hepatitis B core-related antigen (HBcrAg): an alternative to HBV DNA to assess treatment eligibility in Africa. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Audrey Joyce Foka,et al.  Gender development and hepatitis B and C infections among pregnant women in Africa: a systematic review and meta-analysis , 2019, Infectious Diseases of Poverty.

[19]  Minal K. Patel,et al.  Implementing a Birth Dose of Hepatitis B Vaccine in Africa: Findings from Assessments in 5 Countries , 2018, Journal of immunological sciences.

[20]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[21]  R. Jhaveri,et al.  Call to Action: Prevention of Mother-to-Child Transmission of Hepatitis B in Africa. , 2018, The Journal of infectious diseases.

[22]  M. Dickie,et al.  Global Health Sector Strategy on Viral Hepatitis : What does it mean for Canadians ? , 2018 .

[23]  G. Dusheiko,et al.  Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. , 2017, The lancet. Gastroenterology & hepatology.

[24]  R. Tohme,et al.  The status of hepatitis B control in the African region , 2017, The Pan African medical journal.

[25]  N. Berhe,et al.  Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa? , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[26]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[27]  H. Whittle,et al.  Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. , 2016, The Lancet. Global health.

[28]  H. Whittle,et al.  Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia , 2015, Gut.

[29]  Maimuna Mendy,et al.  Validation of Rapid Point-of-Care (POC) Tests for Detection of Hepatitis B Surface Antigen in Field and Laboratory Settings in the Gambia, Western Africa , 2015, Journal of Clinical Microbiology.

[30]  S. Vermund,et al.  Integrated prevention of mother-to-child transmission for human immunodeficiency virus, syphilis and hepatitis B virus in China , 2014, Bulletin of the World Health Organization.

[31]  P. Klenerman,et al.  Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[32]  A. Hall,et al.  Association of Early Age at Establishment of Chronic Hepatitis B Infection with Persistent Viral Replication, Liver Cirrhosis and Hepatocellular Carcinoma: A Systematic Review , 2013, PloS one.

[33]  Gretchen A. Stevens,et al.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. , 2012, Vaccine.

[34]  E. Holmes,et al.  Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. , 2001, Journal of hepatology.

[35]  B. Otto,et al.  At-birth immunisation against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain. , 1999, Vaccine.

[36]  J. Maynard Hepatitis B: global importance and need for control. , 1990, Vaccine.

[37]  W. Szmuness,et al.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B): A final report , 1981, Hepatology.